Clinical trial
Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell…
NCT00169195 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00169195 |
|---|---|
| Title | Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma |
| Official title | Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Hoffmann-La Roche Industry Sanofi-Synthelabo Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) |
| Enrollment | 49 |
| Start date | Apr 1, 2003 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 2, 2015 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: